BMT-136088

BMT-136088 is a high-affinity and selective antagonist of the lysophosphatidic acid receptor 1 (LPA1). It has been developed primarily as a positron emission tomography (PET) imaging agent to quantify LPA1 receptor availability in vivo. The compound is radiolabeled with carbon‑11 ([11C]) for use as a diagnostic radiopharmaceutical in PET studies. Its mechanism of action involves antagonism of the LPA1 receptor, allowing for assessment of target engagement and receptor occupancy in preclinical and clinical research settings. BMT‑136088 was initially developed by Bristol Myers Squibb as a companion diagnostic tool to support drug development targeting LPA1 pathways, particularly in fibrotic diseases such as idiopathic pulmonary fibrosis[1][2][4][6].

Other names

1-(4′-(3-methyl-4-(((1(R)-(3-methylphenyl)ethoxy)carbonyl)amino)isoxazol-5-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid